Pharmacological or genetic intervention investigations validated TRPV1 as a therapeutic target for analgesics, the antagonists of which were proved to be effective for controlling the clinical chronic pain (i.e. cancer, neuropathic, postoperative or musculoskeletal pain) 79. The gene discussed is TRPV1; the disease is cancer.